BMS, Merck, J&J and AbbVie are among the most impacted

With >$175B in cumulative sales at-risk & record amounts of cash on hand for big pharma, the stage appears set for a rebound in M&A

It will be also interesting to see if many of these therapies actually go off-patent at these times, or if their manufacturers will be able to successfully delay generics, as we saw with AbbVie's Humira

Note: LOE = loss of exclusivity